Sugi Predict

Sugi Predict / Compounds / SCHEMBL83271

SCHEMBL83271

SCHEMBL83271

c1cc(Sc2ccc(SCC3CO3)cc2)ccc1SCC1CO1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 4/20 0.40
▸ CHRM4 P08173 4/20 0.40
▸ CHRM5 P08912 4/20 0.40
▸ CHRM1 P11229 4/20 0.40
▸ CHRM3 P20309 3/20 0.40
▸ DRD4 P21917 2/20 0.34
▸ CTSK P43235 1/20 0.33
▸ CYP3A4 P08684 2/20 0.32
▸ TSHR P16473 2/20 0.32
▸ NR1H2 P55055 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.31
▸ CRBN Q96SW2 6/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ HIF1A Q16665 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15700020 1.00 CHRM2 (0.40) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL13366867 0.91 CHRM2 (0.38) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL1402587 0.87 DRD4 (0.34) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL7282254 0.83 CRBN (0.45) DRD4CTSKTSHRMAPK1CRBN
SCHEMBL83272 0.83 DRD4 (0.33) DRD4CTSK
SCHEMBL8847058 0.83 DRD4 (0.48) DRD4CTSKCYP3A4TSHRTDP1
SCHEMBL5143932 0.83 DRD4 (0.47) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL7138364 0.80 RORC (0.38) DRD4CRBNTP53SMN1; SMN2
SCHEMBL4863996 0.80 DRD4 (0.31) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL7607072 0.80 CHRM2 (0.30) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4234641-A1 COMPOSITIONS, COMPRISING MODIFIED TITANIUM DIOXIDE NANOPARTICLES AND USES THEREOF BASF SE (DE) 2023-08-30 — — EP claimed
CN-113855703-A Proton binding polymers for oral administration 特里赛达公司 2021-12-31 — — CN claimed
US-11197887-B2 Proton-binding polymers for oral administration TRICIDA, INC. (US) 2021-12-14 — — US claimed
EP-3593808-B1 PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION TRICIDA INC (US) 2020-12-09 — — EP claimed
CN-111671767-A Proton-binding polymers for oral administration 特里赛达公司 2020-09-18 — — CN claimed
CN-111671766-A Proton-binding polymers for oral administration 特里赛达公司 2020-09-18 — — CN claimed
CN-105377270-B Proton-binding polymers for oral administration 特里赛达公司 2020-09-04 — — CN claimed
EP-3578185-B1 PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION TRICIDA INC (US) 2020-08-05 — — EP claimed
US-20190209607-A1 COMPOSITIONS FOR TREATING ACID-BASE DISORDERS TRICIDA, INC. 2019-07-11 — — US claimed
US-20190169342-A1 POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS RELYPSA, INC. 2019-06-06 — — US claimed
EP-2016114-A2 AMINE CONDENSATION POLYMERS AS PHOSPHATE SEQUESTRANTS Genzyme Corporation (US) 2009-01-21 — — EP claimed
US-20080085259-A1 Amine condensation polymers as phosphate sequestrants GENZYME CORPORATION 2008-04-10 — — US claimed
WO-2007130463-A2 AMINE CONDENSATION POLYMERS AS PHOSPHATE SEQUESTRANTS GENZYME CORPORATION (US) 2007-11-15 — — WO claimed
US-20060041096-A1 Organic-inorganic metal hybrid material and composition for producing organic insulator comprising the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2006-02-23 — — US claimed
US-20040155364-A1 Reworkable thermosetting resin compositions DOBA TAKAHISA (JP) 2004-08-12 — — US claimed
JP-2003502484-A — — 2003-01-21 — — JP claimed
EP-1194953-A4 CONTROLLABLY DEGRADABLE COMPOSITION OF HETEROATOM CARBOCYCLIC OR EPOXY RESIN AND CURING AGENT LOCTITE CORP (US) 2002-09-04 — — EP claimed
EP-1194953-A1 CONTROLLABLY DEGRADABLE COMPOSITION OF HETEROATOM CARBOCYCLIC OR EPOXY RESIN AND CURING AGENT LOCTITE CORPORATION (US) 2002-04-10 — — EP claimed
WO-2000079582-A9 CONTROLLABLY DEGRADABLE COMPOSITION OF HETEROATOM CARBOCYCLIC OR EPOXY RESIN AND CURING AGENT LOCTITE CORP (US) 2001-03-15 — — WO claimed
WO-2000079582-A1 CONTROLLABLY DEGRADABLE COMPOSITION OF HETEROATOM CARBOCYCLIC OR EPOXY RESIN AND CURING AGENT LOCTITE CORPORATION (US) 2000-12-28 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085259-A1 Amine condensation polymers as phosphate sequestrants PHPT1, CEPT1, PNMT CHRM2 1057/4885CHRM4 1641/4885CHRM5 2134/4885
US-20190169342-A1 POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS NR1H4, SLC10A2, ITCH CHRM2 4135/4885CHRM4 3779/4885CHRM5 4155/4885
US-20190209607-A1 COMPOSITIONS FOR TREATING ACID-BASE DISORDERS SLC10A2, SLC10A1, SLC26A3 CHRM2 2467/4885CHRM4 3993/4885CHRM5 3672/4885
US-11197887-B2 Proton-binding polymers for oral administration SLC9A1, HRH2, SLC9A2 CHRM2 3748/4885CHRM4 3947/4885CHRM5 3765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.